Clinical Utilization of Newly Approved Oncology Medications

• Status: Unknown status
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The efficacy and safety of different medications vary from one individual to another and from one ethnic group to another. Therefore, strong interest in the study of pharmacogenomic and pharmacoepidemiology has evolved recently.

There are multiple examples of oncology drugs being more effective in certain ethnic population compared to other. For example, irinotecan combined with cisplatin was very effective drug in the management of small cell lung cancer in the Japanese patients while an identical study done in the US revealed no major benefit to this combination in American population

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Guard Health Affairs

Criteria

Inclusion Criteria:

• All patients with cancer or hematological malignancies receiving new oncology medications (defined as a medication in the first five years of their introduction to the ME market

• Patient accepts to participate in study and signing consent form

Exclusion Criteria:

• None